Clinical trial · Observational

Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim

Immune Counter-Regulation in Melanoma Patients Vaccinated With GM-CSF

NCT01388569CI-TRIAL-00027615completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying samples of blood from patients treated with sargramostim in the laboratory may help doctors learn more about the effects of sargramostim on cells. It may also help doctors understand how patients respond to treatment. PURPOSE: This research trial studies biomarkers in blood samples from patients with stage IV melanoma previously treated with sargramostim.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Melanoma (Skin)	Melanoma	ONTOLOGY_EXACT	0.85

Interventions

Interventions (3)

Intervention	Type	Mapped drug	Match
flow cytometry	Other	—	UNRESOLVED
immunologic technique	Other	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Overall and disease-free survival
timeFrame
1 year

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 120 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Diagnosed with melanoma

  * Stage IV disease
  * HLA-A2\^+ and A2\^+
* Received sargramostim on clinical trial ECOG-4697
* Specimens collected at baseline and either day 43 or day 85 (based on most consistent availability) from long-term survivors and patients with poor survival

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

References

Publications (0)

Data not yet available

No reference posted for this study.